Jürgen Kuball, MD, PhD, Utrecht University, Utrecht, Netherlands, outlines the activity and progress of the EBMT-EHA GoCART initiative, which aims to enhance the potential of chimeric antigen receptor T-cell (CAR-T) therapies by harmonizing the data collected from CAR-T patients across Europe and engaging with different stakeholders to obtain joint accreditations for CAR-Ts that will be produced in their centers. Prof. Kuball also shares his excitement about the scientific projects supported by the GoCART initiative. This interview took place at the EBMT-EHA 4th European CAR T-cell Meeting which was held virtually in 2022.